Leadyond Capital
Leadyond Capital was a private equity firm based in China, established in 2007, that specialized in mid to late-stage investments and buyout transactions. The firm focused on various sectors, including manufacturing, energy, environment, materials, healthcare, financial services, and industrial industries. With a commitment to professional and earnest investment practices, Leadyond Capital sought to uncover the intrinsic value of industries and enterprises, creating new value through specialized services. The firm's approach was characterized by patience and prudence, as it aimed to align strategies and interests with its partners. However, it is important to note that Leadyond Capital is no longer active.
HitGen Inc. operates in the field of early-stage drug discovery, specializing in DNA encoded chemical libraries (DELs) that facilitate the synthesis of diverse small molecules and macrocycle compounds. The company is actively involved in internal research initiatives targeting various therapeutic areas, including oncology, cardiovascular diseases, inflammation, metabolism, and ophthalmology. HitGen collaborates with notable pharmaceutical companies such as Gilead Sciences, Galapagos NV, Kymera Therapeutics, and Morphic Therapeutic to identify potential small molecule leads. Additionally, it has a strategic partnership with Oncodesign Société Anonyme aimed at discovering and developing new chemical entities. Founded in 2012 and based in Chengdu, China, HitGen also provides biological reagents and services to support drug discovery research, along with technology transfer and technical consultation related to drug development projects.
HitGen Inc. operates in the field of early-stage drug discovery, specializing in DNA encoded chemical libraries (DELs) that facilitate the synthesis of diverse small molecules and macrocycle compounds. The company is actively involved in internal research initiatives targeting various therapeutic areas, including oncology, cardiovascular diseases, inflammation, metabolism, and ophthalmology. HitGen collaborates with notable pharmaceutical companies such as Gilead Sciences, Galapagos NV, Kymera Therapeutics, and Morphic Therapeutic to identify potential small molecule leads. Additionally, it has a strategic partnership with Oncodesign Société Anonyme aimed at discovering and developing new chemical entities. Founded in 2012 and based in Chengdu, China, HitGen also provides biological reagents and services to support drug discovery research, along with technology transfer and technical consultation related to drug development projects.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.